Onkologie. 2025:19(1):33-36 | DOI: 10.36290/xon.2025.008

Treatment options for KRAS G12C mutated metastatic colorectal cancer

Marián Liberko
Onkologická klinika, Fakultní nemocnice Královské Vinohrady, 3. LF UK, Praha

Metastatic colorectal cancer is a heterogeneous disease where treatment is individually selected according to the knowledge of the molecular characteristics of the tumour. As the knowledge of the molecular biology of the disease increases, the number of potential targets for specific therapies increases. In recent years, KRAS G12C inhibitor therapy has become a new treatment option for patients with metastatic colorectal cancer with a proven KRAS G12C mutation. The aim of this article is to provide an overview of current treatment options for this entity.

Keywords: metastatic colorectal cancer, RAS mutation, sotorasib, anti-EGFR therapy.

Accepted: February 27, 2025; Published: March 10, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Liberko M. Treatment options for KRAS G12C mutated metastatic colorectal cancer. Onkologie. 2025;19(1):33-36. doi: 10.36290/xon.2025.008.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • PDF will be unlocked 10.3.2026

    References

    1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality World­wide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209-249. Go to original source... Go to PubMed...
    2. Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treat­ment and follow-up. Ann Oncol. 2023;34:10-32. Go to original source... Go to PubMed...
    3. Hofmann MH, Gerlach D, Misale S, et al. Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants. Cancer Discov. 2022;12:924-937. Go to original source... Go to PubMed...
    4. Lee JK, Sivakumar S, Schrock AB, et al. Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. Precision Oncology. 2022;6(1):1-14. Go to original source... Go to PubMed...
    5. Prior IA, Hood FE, Hartley JL. The frequency of ras muta­tions in cancer. Cancer Res. 2020;80:2669-2974. Go to original source... Go to PubMed...
    6. Rubinson DA, Tanaka N, Fece de la Cruz F. Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers. Cancer Discov. 2024;14:727-736. Go to original source... Go to PubMed...
    7. Shih C, Weinberg RA. Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell. 1982;29:161-169. Go to original source... Go to PubMed...
    8. Goldfarb M, Shimizu K, Percho M, et al. Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells. Nature. 1982;296(5856): 404-409. Go to original source... Go to PubMed...
    9. Pulciani S, Santos E, Lauver AV, et al. Oncogenes in human tumor cell lines: molecular cloning of a transforming gene from human bladder carcinoma cells. Proc Natl Acad Sci U S A. 1982;79:2845-2849. Go to original source... Go to PubMed...
    10. Lièvre A, Bachet JB, Le Corre D. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2009;66:3992-3995. Go to original source... Go to PubMed...
    11. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532-536. Go to original source... Go to PubMed...
    12. Neumann J, Zeindl-Eberhart E, Kirchner T, et al. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract. 2009;205:858-862. Go to original source... Go to PubMed...
    13. Sorich MJ, Wiese MD, Rowland A, et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: A meta-analysis of randomized, controlled trials. Annals of Oncology. 2015;26:13-21. Go to original source... Go to PubMed...
    14. Lu S, Jang H, Nussinov R, et al. The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B. Scientific Reports. 2016;6(1):1-15. Go to original source... Go to PubMed...
    15. Huang L, Guo Z, Wang F, et al. KRAS mutation: from undrug­gable to druggable in cancer. Signal Transduction and Targeted Therapy. 2021;6(1):1-20. Go to original source... Go to PubMed...
    16. Ostrem JM, Peters U, Sos ML, et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503:548. Go to original source... Go to PubMed...
    17. Janes MR, Zhang J, Li LS, Hansen R, et al. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. Cell. 2018;172:578-589.e17. Go to original source... Go to PubMed...
    18. Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575:217-223. Go to original source... Go to PubMed...
    19. Hallin J, Engstrom LD, Hargis L, et al. The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. Cancer Discov. 2020;10:54-71. Go to original source... Go to PubMed...
    20. Strickler JH, Yoshino T, Stevinson K, et al. Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review. Oncologist. 2023;28:E981-E994. Go to original source... Go to PubMed...
    21. Henry JT, Coker O, Chowdhury S, et al. Comprehensive Clinical and Molecular Characterization of KRAS G12C-Mutant Colorectal Cancer. JCO Precis Onco. 2021;5:613-621. Go to original source... Go to PubMed...
    22. Fakih M, Tu H, Hsu H, et al. Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer. Oncologist. 2022;27:663-674. Go to original source... Go to PubMed...
    23. Hong DS, Fakih MG, Strickler JH, et al. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med. 2020;383:1207-1217. Go to original source... Go to PubMed...
    24. Fakih MG, Kopetz S, Kuboki Y, et al. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol. 2022;23:115-124. Go to original source... Go to PubMed...
    25. Ou SI, Jänne PA, Leal TA, et al. First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1). J Clin Oncol. 2022;40:2530-2538. Go to original source... Go to PubMed...
    26. Yaeger R, Weiss J, Pelster MS, et al. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023;388:44-54. Go to original source... Go to PubMed...
    27. Purkey H. Abstract ND11: Discovery of GDC-6036, a clinical stage treatment for KRAS G12C-positive cancers. Cancer Res. 2022;82:ND11-ND11. Go to original source...
    28. Sacher A, LoRusso P, Patel MR, et al. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. N Engl J Med. 2023;389:222. Go to original source... Go to PubMed...
    29. Amodio V, Yaeger R, Arcella P, et al. EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. Cancer Discov. 2020;10:1129-1139. Go to original source... Go to PubMed...
    30. Kuboki Y, Fakih M, Strickler J, et al. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nat Med. 2024; 30:265-270. Go to original source... Go to PubMed...
    31. Fakih MG, Salvatore L, Esaki T, et al. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023;389:2125-2139. Go to original source... Go to PubMed...
    32. Fakih M, Salvatore L, Esaki T, et al. Overall survival (OS) of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab (soto+pani) versus investigator's choice of therapy for KRAS G12C-mutated metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 2024;42:LBA3510-LBA3510. Go to original source...
    33. Desai J, Alonso G, Kim SH, et al. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. Nature Medicine. 2023;30(1):271-278. Go to original source... Go to PubMed...
    34. Wei D, Wang L, Zuo X, et al. A small molecule with big impact: MRTX1133 targets the KRASG12D mutation in pancreatic cancer. Clin Cancer Res. 2024;30:655. Go to original source... Go to PubMed...
    35. Kim D, Herdeis L, Rudolph D, et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature. 2023;619:160-166. Go to original source... Go to PubMed...
    36. Arbour KC, Punekar S, Garrido-Laguna I, et al. 652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). Annals of Oncology. 2023;34:S458. Go to original source...
    37. Wasko UN, Jiang J, Dalton TC, et al. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Nature. 2024;629:927-936. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.